Oramed Pharmaceuticals Inc. – ORAMED PHARMACEUTICALS INC. equity distribution AGREEMENT (September 5th, 2019)
Oramed Pharmaceuticals Inc. – Employment Agreement (July 10th, 2019)This Employment Agreement is made on 16th day of May 2019, by and between Avi Gabay, an individual residing in Modiin, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – Amendment #2 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC BASIC PROVISIONS (July 10th, 2019)Study Title: (the “Study”): “A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients with Inadequate Glycemic Control on Oral Therapy”
Oramed Pharmaceuticals Inc. – Amendment #1 to Clinical Research Organization Services Agreement Protocol # ORA-D-015 between Oramed, Inc. and Integrium, LLC BASIC PROVISIONS (July 10th, 2019)This Amendment #1 (“First Amendment”) to the Contract Research Organization Agreement (the “Agreement”) made this 18th day of April, 2019, by and between Oramed Ltd. (“Sponsor”), an Israeli company, with principal offices located at Hi-Tech Park 2/4 Givat-Ram, P.O. Box 39098, Jerusalem, 91390, Israel (“Sponsor”), and Integrium, LLC., a California limited liability company with its principal place of business located at 14351 Myford Road, Suite A, Tustin, CA 92780 (“Integrium”).
Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT (July 10th, 2019)THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
Oramed Pharmaceuticals Inc. – Consulting Agreement (January 14th, 2019)This Consulting Agreement (this “Agreement”) is entered into on this 12th day of December, 2018 by and between Oramed Pharmaceuticals Inc., a Delaware corporation having a principal place of business at 142 W. 57th Street, 11th Floor, New York, NY 10019 (“Oramed”), and Joshua Hexter, an individual residing at 7550 Amherst Avenue, University City, MO, 63130 (“Consultant”).
Oramed Pharmaceuticals Inc. – Employment Agreement (November 28th, 2018)This Employment Agreement is entered into as of this 6 day of November 2018, by and between Mark Hasleton, an individual residing in Ra’anana, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – First Amendment to Amended and Restated Employment Agreement (November 28th, 2018)This First Amendment to Amended and Restated Employment Agreement (this “First Amendment”) is entered into as of this 29th day of October 2018 and is effective as of May 1, 2018, by and between Hilla Eisenberg, an individual residing in Haifa, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT (November 28th, 2018)THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
Oramed Pharmaceuticals Inc. – Third Amendment to Employment Agreement (July 12th, 2018)This Third Amendment to the Employment Agreement (this “Third Amendment”) is entered into as of this 15th day of April 2018, by and between Joshua Hexter, an individual residing in Jerusalem, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – STRICTLY CONFIDENTIAL (July 5th, 2018)This amended and restated letter agreement (this “Agreement”), which amends and restates in its entirety that certain engagement letter, dated as of June 28, 2018, entered into by the parties hereto, constitutes the agreement between Oramed Pharmaceuticals Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the U.S. exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation an
Oramed Pharmaceuticals Inc. – SECURITIES PURCHASE AGREEMENT (July 5th, 2018)This Securities Purchase Agreement (this “Agreement”) is dated as of July 2, 2018, between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Oramed Pharmaceuticals Inc. – COMMON STOCK PURCHASE WARRANT Oramed Pharmaceuticals Inc. (July 5th, 2018)THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six (6) months anniversary of the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Oramed Pharmaceuticals Inc. – **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** CLINICAL RESEARCH ORGANIZATION SERVICES AGREEMENT By and Between Oramed Ltd. and Integrium, LLC Effective Date: November 1, 2017 (April 9th, 2018)Oramed Ltd. (“Sponsor”), an Israeli company, with principal offices at Hi-Tech Park 2/4 Givat-Ram, P.O. Box 39098, Jerusalem, 91390, Israel and Integrium, LLC, (“Integrium”), a California limited liability company, located at 14351 Myford Road, Suite A, Tustin, California, 92780, hereby agree as follows:
Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT (November 29th, 2017)THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
Oramed Pharmaceuticals Inc. – ORAMED PHARMACEUTICALS INC. SECOND AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN Restricted Stock Unit Notice (November 29th, 2017)This Restricted Stock Unit Agreement and the associated restricted stock unit notice (the “Customizing Information”), which Customizing Information is available in written or electronic form from the Chief Financial Officer of Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), is made as of the date shown as the “Grant Date” in the Customizing Information (the “Grant Date”) by and between the Company, and the individual identified in the Customizing Information (the “Grantee”). This instrument and the Customizing Information is collectively referred to as the “Restricted Stock Unit Agreement.”
Oramed Pharmaceuticals Inc. – AGREEMENT AND AMENDMENT NO. 5 (November 29th, 2017)This AGREEMENT AND AMENDMENT NO. 5 (this “Fifth Amendment”) is made this 30 day of June, 2017 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Oramed Pharmaceuticals Inc. – CERTIFICATE OF CORRECTION TO CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ORAMED PHARMACEUTICALS INC. Pursuant to Section 103(f) of the General Corporation Law of the State of Delaware (September 5th, 2017)Oramed Pharmaceuticals Inc., a corporation incorporated and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”)
Oramed Pharmaceuticals Inc. – Amended and Restated Employment Agreement (July 21st, 2017)This Amended and Restated Employment Agreement is entered into as of this 20th day of July 2017, by and between Hilla Eisenberg, an individual residing at Tel-Aviv, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the ”Company”).
Oramed Pharmaceuticals Inc. – AMENDMENT NO. 1 TO AT-THE-MARKET ISSUANCE SALES AGREEMENT (April 5th, 2017)Oramed Pharmaceuticals Inc. (the “Company”), and MLV & Co. LLC (“MLV”), are parties to that certain At-the-Market Issuance Sales Agreement dated April 2, 2015 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. Whereas MLV desires to resign as sales agent and the Company desires to appoint FBR Capital Markets & Co. (“FBR”) as sales agent, the parties, intending to be legally bound, hereby amend the Original Agreement as follows:
Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT (April 5th, 2017)THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
Oramed Pharmaceuticals Inc. – Consulting Agreement (March 21st, 2017)This Consulting Agreement (this “Agreement”) is entered into as of this 01 day of March 2017 (“Effective Date”), by and between Mr. Ronald Law, Ph.D., J.D. residing at 23733 N. Lookout Pointe Road, Lake Barrington, IL 60010, U.S.A. (“Consultant”) and Oramed Ltd., Company Number 513976712, a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – INDEMNIFICATION AGREEMENT (January 11th, 2017)THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of August 30, 2016 between Oramed Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Kevin Rakin (“Indemnitee”).
Oramed Pharmaceuticals Inc. – Fourth Amendment to Employment Agreement (January 11th, 2017)This Fourth Amendment to the Employment Agreement (this “Fourth Amendment”) is entered into as of this 28 day of November 2016, by and between Yifat Zommer, an individual residing at Rehovot, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – AGREEMENT AND AMENDMENT NO. 5 (January 11th, 2017)This AGREEMENT AND AMENDMENT NO. 5 (this “Fifth Amendment”) is made this 28 day of November, 2016 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Oramed Pharmaceuticals Inc. – **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** AMENDMENT AGREEMENT (November 25th, 2016)THIS AMENDMENT AGREEMENT, dated as of July 24, 2016, is entered into by and between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT”); and Oramed Pharmaceuticals Inc., a Delaware corporation and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (collectively referred to as “Oramed”).
Oramed Pharmaceuticals Inc. – **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** General Technical Agreement (November 25th, 2016)This General Technical Agreement (this “Agreement”) is entered into as of July 24, 2016 (the “Effective Date”) by and between Oramed Ltd., a company organized under the laws of the State of Israel, with its offices at 2/4 Kefar Hi-tech, PO Box 39098, Jerusalem, 91390, Israel, and with the following facsimile number +972-2-566-0004 and email address josh@oramed.com (“Oramed”), and PREMAS Biotech Pvt. Ltd, a company organized under the laws of India, with its offices at Plot 77, Sector 4, IMT Manesar, Gurgaon 122050, Haryana, India, and with an email address prabuddha.kundu@premasbiotech.com (“Premas”).
Oramed Pharmaceuticals Inc. – Second Amendment to Employment Agreement (November 25th, 2016)This Second Amendment to the Employment Agreement (this “Second Amendment”) is entered into as of this 27 day of June 2016, by and between Joshua Hexter, an individual residing at Jerusalem, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Oramed Pharmaceuticals Inc. – AGREEMENT AND AMENDMENT NO. 4 (November 25th, 2016)This AGREEMENT AND AMENDMENT NO. 4 (this “Forth Amendment”) is made this 27 day of June, 2016 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Oramed Pharmaceuticals Inc. – AGREEMENT (November 25th, 2016)This Agreement (the “Agreement”) is entered into as of June 3, 2016 (the “Effective Date”) between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China (“PRC”) and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT”), and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (“Oramed”). HTIT and Oramed are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Oramed Pharmaceuticals Inc. – AGREEMENT AND AMENDMENT NO. 4 (November 25th, 2016)This AGREEMENT AND AMENDMENT NO. 4 (this “Forth Amendment”) is made this 27 day of June, 2016 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Oramed Pharmaceuticals Inc. – **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”).** service Agreement between oramed ltd. and xertecs gmbh (November 25th, 2016)Oramed Ltd., a company organized under the laws of the State of Israel, with its offices at 2/4 Kefar Hi-tech, PO Box 39098, Jerusalem, 91390, Israel, hereafter referred to as “ORAMED”,
Oramed Pharmaceuticals Inc. – **Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** AMENDED AND RESTATED TECHNOLOGY License AGREEMENT (January 13th, 2016)This Amended and Restated Technology License Agreement (the “Agreement”) is entered into as of December 21, 2015 (the “Execution Date”) between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China (“PRC”) and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT” or “Licensee”); and Oramed Pharmaceuticals Inc., a Delaware corporation and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (collectively referred to as “Oramed”). HTIT and Oramed are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Oramed Pharmaceuticals Inc. – January 6, 2016 (January 6th, 2016)
Oramed Pharmaceuticals Inc. – Third Amendment to Employment Agreement (November 25th, 2015)This Third Amendment to the Employment Agreement (this “Third Amendment”) is entered into as of this 21 day of July 2015, by and between Yifat Zommer, an individual residing at Rehovot, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
